| MeSH term | MeSH ID | Detail |
|---|---|---|
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Postoperative Complications | D011183 | 5 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Neoplasm Recurrence, Local | D009364 | 5 associated lipids |
| Osteonecrosis | D010020 | 5 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Heath M and Raugi GJ | Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus. | 2004 | Adv Dermatol | pmid:15544204 |
| Gonin JM | Maintenance immunosuppression: new agents and persistent dilemmas. | 2000 | Adv Ren Replace Ther | pmid:10782729 |
| Ginocchio L et al. | Refractory Ulcerated Necrobiosis Lipoidica: Closure of a Difficult Wound with Topical Tacrolimus. | 2017 | Adv Skin Wound Care | pmid:28914682 |
| Balal M et al. | Effects of cyclosporine and tacrolimus on maintenance therapy after renal transplantation. | 2004 May-Jun | Adv Ther | pmid:15509135 |
| Diao H et al. | Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact lens-induced papillary conjunctivitis. | 2012 | Adv Ther | pmid:22821643 |
| Hon KL et al. | Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment. | 2007 Jan-Feb | Adv Ther | pmid:17526458 |
| Mancilla UE et al. | Primary immunosuppression with tacrolimus in renal transplantation: a multicenter, open-label study. | 1999 Sep-Oct | Adv Ther | pmid:10915396 |
| Lionetti P et al. | Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. | 1995 | Adv. Exp. Med. Biol. | pmid:8525974 |
| Mori A et al. | Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. | 1996 | Adv. Exp. Med. Biol. | pmid:9095279 |
| Shahidi M | Thrombosis and von Willebrand Factor. | 2017 | Adv. Exp. Med. Biol. | pmid:27628010 |
| Clemann N and Bechter R | Effects of rapamycin and FK 506 on rat Sertoli cells in vitro. | 1998 | Adv. Exp. Med. Biol. | pmid:10026935 |
| Thomson AW and Bonham CA | Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. | 1995 | Adv. Exp. Med. Biol. | pmid:7572394 |
| Abramowicz D et al. | Immunosuppressive strategies in renal transplantation at the beginning of the third millennium. | 2000 | Adv. Nephrol. Necker Hosp. | pmid:11068631 |
| Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
| Doren EL and Aya-ay ML | Pyoderma gangrenosum following breast reduction: treatment with topical tacrolimus and steroids. | 2014 | Aesthet Surg J | pmid:24448967 |
| Bolton C | The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). | 1992 | Agents Actions | pmid:1380765 |
| Griffiths RJ et al. | Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. | 1992 | Agents Actions | pmid:1384284 |
| MartÃn-Cano FE et al. | mTOR pathway and Ca²⺠stores mobilization in aged smooth muscle cells. | 2013 | Aging (Albany NY) | pmid:23661091 |
| Sekigawa I et al. | FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. | 1994 | AIDS | pmid:7531458 |
| Antonini TM et al. | Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. | 2015 | AIDS | pmid:25387314 |
| Florio G et al. | The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. | 2000 | AIDS | pmid:10853974 |
| Nowak P et al. | Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. | 2003 | AIDS Res. Hum. Retroviruses | pmid:12581512 |
| Sklar EM | Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? | 2006 | AJNR Am J Neuroradiol | pmid:16971594 |
| Bargalló N et al. | Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. | 2000 | AJNR Am J Neuroradiol | pmid:10730638 |
| Bartynski WS et al. | Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. | 2001 Nov-Dec | AJNR Am J Neuroradiol | pmid:11733324 |
| Bartynski WS et al. | Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. | 2004 | AJNR Am J Neuroradiol | pmid:14970028 |
| Bartynski WS et al. | Posterior reversible encephalopathy syndrome after solid organ transplantation. | 2008 | AJNR Am J Neuroradiol | pmid:18272559 |
| Schuuring J et al. | Severe tacrolimus leukoencephalopathy after liver transplantation. | 2003 Nov-Dec | AJNR Am J Neuroradiol | pmid:14625238 |
| Oliverio PJ et al. | Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. | 2000 | AJNR Am J Neuroradiol | pmid:10954277 |
| Appignani BA et al. | Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. | 1996 | AJR Am J Roentgenol | pmid:8623651 |
| Baumgart DC et al. | Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755840 |
| Srinivas NR | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589592 |
| BenÃtez C et al. | Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28589580 |
| Itoh S et al. | Inhibition of CN (protein phosphatase-2B) suppresses Ca2+-mediated acid secretion in rats. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966520 |
| Yamamoto S et al. | Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. | 2008 | Aliment. Pharmacol. Ther. | pmid:18549460 |
| O'Leary JG | Editorial: tacrolimus-how low can you go? | 2017 | Aliment. Pharmacol. Ther. | pmid:28589579 |
| Herrlinger KR et al. | Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20175769 |
| Solari S et al. | Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. | 2017 | Aliment. Pharmacol. Ther. | pmid:28261844 |
| Schwrer H et al. | Pantoprazole and cyclosporine or tacrolimus. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284790 |
| Högenauer C et al. | Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12940927 |
| Trotter JF et al. | Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963078 |
| Nakase H et al. | Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy. | 2011 | Aliment. Pharmacol. Ther. | pmid:21434949 |
| Nakase H et al. | Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? | 2011 | Aliment. Pharmacol. Ther. | pmid:21198700 |
| Liberal R et al. | Expert clinical management of autoimmune hepatitis in the real world. | 2017 | Aliment. Pharmacol. Ther. | pmid:28004405 |
| Segal JP et al. | Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. | 2017 | Aliment. Pharmacol. Ther. | pmid:28008631 |
| Mehta SJ et al. | Review article: strategies for the management of chronic unremitting ulcerative colitis. | 2013 | Aliment. Pharmacol. Ther. | pmid:23718288 |
| Yamamoto T et al. | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040167 |
| Taylor KM and Sparrow MP | Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. | 2016 | Aliment. Pharmacol. Ther. | pmid:27040166 |
| Haagsma EB et al. | Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848624 |
| Nakase H et al. | Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20636704 |